INTRODUCTION: Gastric cancer is the second leading cause of cancer mortality in the world. Whether the oncogene, amplified on chromosome 3q26, SOX2, a master transcriptional regulator of stemness, operate to drive strong growth phenotype in gastric cancer were unknown. MATERIALS AND METHODS: The gene expression changes of SOX2 in human gastric cancer tissues compared with non-cancerous tissues was detected using real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohistochemistry, which identified the gene overexpression of SOX2 in gastric cancer. Moreover, we discovered that SOX2 promoted cancer cell proliferation in vitro/vivo and SOX2 expression correlated with elevated AKT phosphorylation in gastric cancer, while the AKT phosphorylation was required for SOX2's oncogenic effects. Next, our data point to the usefulness of SOX2 overexpression, as a new predictive marker for responsiveness to trastuzumab. CONCLUSION: SOX2 is a commonly activated tumor promoter that activate AKT signaling in gastric cancer and a new predictive marker for targeted therapy.
INTRODUCTION:Gastric cancer is the second leading cause of cancer mortality in the world. Whether the oncogene, amplified on chromosome 3q26, SOX2, a master transcriptional regulator of stemness, operate to drive strong growth phenotype in gastric cancer were unknown. MATERIALS AND METHODS: The gene expression changes of SOX2 in humangastric cancer tissues compared with non-cancerous tissues was detected using real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohistochemistry, which identified the gene overexpression of SOX2 in gastric cancer. Moreover, we discovered that SOX2 promoted cancer cell proliferation in vitro/vivo and SOX2 expression correlated with elevated AKT phosphorylation in gastric cancer, while the AKT phosphorylation was required for SOX2's oncogenic effects. Next, our data point to the usefulness of SOX2 overexpression, as a new predictive marker for responsiveness to trastuzumab. CONCLUSION:SOX2 is a commonly activated tumor promoter that activate AKT signaling in gastric cancer and a new predictive marker for targeted therapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: J G Park; H Frucht; R V LaRocca; D P Bliss; Y Kurita; T R Chen; J G Henslee; J B Trepel; R T Jensen; B E Johnson Journal: Cancer Res Date: 1990-05-01 Impact factor: 12.701
Authors: Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy Journal: Nature Date: 2003-02-13 Impact factor: 49.962
Authors: Peter Nagy; Elza Friedländer; Minna Tanner; Anita I Kapanen; Kermit L Carraway; Jorma Isola; Thomas M Jovin Journal: Cancer Res Date: 2005-01-15 Impact factor: 12.701
Authors: Christiane Knuefermann; Yang Lu; Bolin Liu; Weidong Jin; Ke Liang; Ling Wu; Mathias Schmidt; Gordon B Mills; John Mendelsohn; Zhen Fan Journal: Oncogene Date: 2003-05-22 Impact factor: 9.867
Authors: Timothy Kute; Christopher M Lack; Mark Willingham; Bimjhana Bishwokama; Holly Williams; Kathy Barrett; Tanita Mitchell; James P Vaughn Journal: Cytometry A Date: 2004-02 Impact factor: 4.355
Authors: David H Tompkins; Valérie Besnard; Alexander W Lange; Susan E Wert; Angela R Keiser; April N Smith; Richard Lang; Jeffrey A Whitsett Journal: PLoS One Date: 2009-12-14 Impact factor: 3.240
Authors: Eva Sodja; Matija Rijavec; Ana Koren; Aleksander Sadikov; Peter Korošec; Tanja Cufer Journal: Radiol Oncol Date: 2016-04-23 Impact factor: 2.991
Authors: Erin L Wuebben; Phillip J Wilder; Jesse L Cox; James A Grunkemeyer; Thomas Caffrey; Michael A Hollingsworth; Angie Rizzino Journal: Oncotarget Date: 2016-06-07